Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Jan;204(1):54.e1-5.
doi: 10.1016/j.ajog.2010.08.022.

Women with preterm premature rupture of the membranes do not benefit from weekly progesterone

Christian M Briery  1 , Edward W Veillon, Chad K Klauser, Rick W Martin, Everett F Magann, Suneet P Chauhan, John C Morrison
Affiliations
Randomized Controlled Trial

Women with preterm premature rupture of the membranes do not benefit from weekly progesterone

Christian M Briery et al. Am J Obstet Gynecol. 2011 Jan.

Abstract

Objective: We sought to determine if 17-alpha-hydroxyprogesterone (17P) extends gestation vs placebo in women with preterm premature rupture of the membranes (PPROM).

Study design: Women with vertex presentations with PPROM, 20-30 weeks' gestation, were randomized to receive weekly 17P or placebo in an attempt to prolong the pregnancy. A total of 69 patients (17P, n = 33; placebo, n = 36) were randomized into this study.

Results: Initial cervical dilatation, gestational age at enrollment, and interval to delivery were not different between the 2 groups (P = .914, .424, and .146, respectively). Time of randomization to delivery (P = .250), mode of delivery (relative risk, 1.16; 95% confidence interval, 0.66-2.06), and the neonatal outcome statistics of morbidity (P = .820) and mortality (relative risk, 1.28; 95% confidence interval, 0.59-2.75) were similar between the 2 groups.

Conclusion: In patients with PPROM, 17P did not extend gestation vs placebo and cannot be recommended for treatment in such women.

Trial registration: ClinicalTrials.gov NCT00830765.

PubMed Disclaimer

Publication types

Substances

Associated data